- Home
- VANI vs CNTB Comparison
VANI vs CNTB Comparison
Compare VANI & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VANI | CNTB |
|---|---|---|
| Founded | 1998 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.0M | 140.4M |
| IPO Year | 2014 | 2020 |
Fundamental Metrics
Financial Performance| Metric | VANI | CNTB |
|---|---|---|
| Price | $1.24 | $1.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $3.50 | ★ $8.67 |
| AVG Volume (30 Days) | 199.0K | ★ 1.7M |
| Earning Date | 05-14-2026 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,000,000.00 | $64,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.92 | $1.06 |
| 52 Week High | $1.92 | $3.82 |
Technical Indicators
Market Signals| Indicator | VANI | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 42.25 | 29.96 |
| Support Level | $1.17 | N/A |
| Resistance Level | $1.25 | $2.78 |
| Average True Range (ATR) | 0.06 | 0.15 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 18.18 | 0.00 |
Price Performance
Historical ComparisonAbout VANI Vivani Medical Inc. (DE)
Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.